TD Asset Management Inc Purchases 26,602 Shares of DaVita Inc. $DVA

TD Asset Management Inc boosted its position in shares of DaVita Inc. (NYSE:DVA) by 155.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 43,754 shares of the company’s stock after purchasing an additional 26,602 shares during the period. TD Asset Management Inc owned about 0.06% of DaVita worth $5,814,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in DVA. Hantz Financial Services Inc. increased its holdings in shares of DaVita by 48.1% during the second quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after buying an additional 75 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in DaVita during the 2nd quarter valued at $43,000. Employees Retirement System of Texas acquired a new stake in DaVita during the 2nd quarter valued at $49,000. SJS Investment Consulting Inc. raised its position in DaVita by 3,091.7% in the 3rd quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock valued at $51,000 after purchasing an additional 371 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in DaVita by 34.9% in the third quarter. Smartleaf Asset Management LLC now owns 452 shares of the company’s stock worth $59,000 after purchasing an additional 117 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

Shares of NYSE DVA opened at $152.25 on Wednesday. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $159.42. The firm has a market capitalization of $10.17 billion, a P/E ratio of 15.36, a P/E/G ratio of 0.54 and a beta of 0.94. The company’s 50 day simple moving average is $125.68 and its 200 day simple moving average is $126.16.

DaVita (NYSE:DVA) last issued its earnings results on Monday, February 2nd. The company reported $3.40 EPS for the quarter, beating the consensus estimate of $3.24 by $0.16. The company had revenue of $3.62 billion during the quarter, compared to analysts’ expectations of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. Sell-side analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. UBS Group lifted their price target on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a report on Wednesday, February 4th. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. TD Cowen reiterated a “hold” rating on shares of DaVita in a research report on Tuesday, February 3rd. Barclays increased their price target on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 3rd. Finally, Truist Financial set a $158.00 price objective on shares of DaVita in a research report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $155.80.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.